Meeting Highlights in Myelofibrosis from the ASH Annual Meeting
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.
Release Date: May 09, 2023
Expiration Date: May 09, 2024
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
In this activity, three myelofibrosis experts discuss how new advances and research should be applied in clinical practice using updated data presented at the ASH annual meeting. Determining the optimal course of action following JAK inhibitor treatment failure/intolerance/disease progression is extremely difficult because there is no standard course of action. Fortunately, research is identifying new agents that appear to be effective either alone or when combined with ruxolitinib in newly diagnosed and/or progressing patients.
This educational activity is designed for community-based hematologists, hematologist/oncologists and community-based advanced practice providers in hematology/oncology who provide care to patients with myelofibrosis.
Upon completion of this educational activity, participants should be able to:
- Recount data presented at the ASH annual meeting examining ongoing studies focusing on MF treatment
- Identify practice implications from recent clinical data on MF treatment
Meeting Highlights in Myelofibrosis from the ASH Annual Meeting – Andrew Kuykendall, MD, Haris Ali, MD, and Stephen T. Oh, MD, PhD
Instructions for Participation and Credit
This activity is eligible for credit through May 09, 2024. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Andrew Kuykendall, MD
Moffitt Cancer Center
Department of Malignant Hematology
Morsani College of Medicine
Dr. Andrew Kuykendall obtained his medical degree from the University of Florida College of Medicine. He completed an Internal Medicine residency at the University of South Florida and a subsequent Hematology and Medical Oncology fellowship at Moffitt Cancer Center/University of South Florida. Dr. Kuykendall is an Assistant Professor at Moffitt Cancer Center in the Department of Malignant Hematology in Tampa, Florida.
Dr. Kuykendall primarily focuses his clinical and research efforts on myeloproliferative neoplasms (MPNs), MDS/MPN overlap syndromes and systemic mastocytosis (SM) where he is dedicated to developing novel, disease-modifying therapies for these rare diseases. He is the primary investigator of numerous clinical trials and an active member of the MPN-Research Consortium – a collaborative effort aimed at improving therapeutic options for MPN patients by rationally and efficiently developing disease-modifying therapies.
Haris Ali, MD
MPN Section Leader
Division of Leukemia
Department of Hematology and
Hematopoietic Cell Transplantation
City of Hope
Dr. Haris Ali received his medical degree Rawalpindi Medical College, Rawalpindi, Pakistan. He completed an internal medicine residency at Loma Linda University Medical Center. Dr. Ali completed fellowships in Hematology & Medical Oncology at the University of Texas Southwestern Medical Center, Dallas, Texas and in Hematology & Hematopoietic Cell Transplantation at City of Hope Comprehensive Cancer Center in Duarte, California. He is currently an Associate Professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California.
Dr. Ali’s clinical practice and research focus on myeloproliferative neoplasms (MPNs) and graft versus host disease after stem cell transplantation. He has been a principal investigator for numerous studies and has published over 40 peer-reviewed articles.
Stephen T. Oh, MD, PhD
Department of Medicine
Department of Pathology & Immunology
Washington University School of Medicine
St. Louis, Missouri
Dr. Stephen Oh received his medical degree and PhD from Northwestern University Feinberg School of Medicine in Chicago. He completed an internal medicine residency, hematology/oncology fellowship, and postdoctoral fellowship at Stanford University School of Medicine, Stanford, California. He is an Associate Professor of Medicine and Co-Chief of the Division of Hematology at Washington University School of Medicine, St. Louis, Missouri.
Dr. Oh’s clinical practice and research efforts are focused on myeloproliferative neoplasms (MPNs). His laboratory investigates fundamental mechanisms driving the initiation, development, and progression of MPNs. Dr. Oh has extensive clinical experience in the diagnosis and management of MPN patients and has contributed to numerous clinical trials investigating novel targeted therapies for MPN patients. The long-term objective of his work is to translate the findings from his laboratory research into improved therapies for MPN patients.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit.
Universal Activity Number: 827-0000-23-012-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
MediCom Worldwide, Inc.is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 23-012-169.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.
Dr. Andrew Kuykendall has relevant financial relationships related to advisory activities from AbbVie Inc., Blueprint Medicines (relationship has ended), Celgene Corporation ‒ A Bristol Myers Squibb Company, CTI BioPharma Corp. (relationship has ended), Imago BioSciences (relationship has ended), Incyte Corporation (relationship has ended), Novartis AG (relationship has ended), and Sierra Oncology, Inc. He is on the speakers’ bureau for Blueprint Medicines (relationship has ended), Celgene Corporation ‒ A Bristol Myers Squibb Company, and Incyte, and has received research grant(s) from Blueprint Medicines (relationship has ended), Celgene Corporation ‒ A Bristol Myers Squibb Company, and Sierra Oncology.
Dr. Haris Ali has relevant financial relationships related to consulting from Incyte Corporation, Bristol Myers Squibb Company, AbbVie Inc., CTI BioPharma Corp., Karyopharm, and PharmaEssentia Corporation. He is on the speakers’ bureau for Incyte, Bristol Myers Squibb, and PharmaEssentia, and has received research grant(s) from Incyte.
Dr. Stephen Oh has relevant financial relationships related to consulting from AbbVie Inc., Bristol Myers Squibb Company, Cogent Biosciences, Inc., Constellation Pharmaceuticals, CTI BioPharma Corp., Geron, Incyte Corporation, Protagonist, and Sierra Oncology, Inc. (now GSK plc) (all relationships listed have ended).
All of the relevant financial relationships listed for these individuals have been mitigated.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Joan Meyer, RN, MHA, Executive Director and Cassie Rametta, Senior Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Constellation Pharmaceuticals Inc., A MorphoSys Company and Incyte Corporation.
©2023 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.